How to appeal an Aetna plaque psoriasis + psoriatic arthritis denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for plaque psoriasis + psoriatic arthritis

Cited policy: Aetna CPB on Bimzelx (Bimekizumab-bkzx)

Plaque: BSA >=10% OR PASI >=12 OR special-site OR DLQI >=10. Trial + failure of >=2 systemic agents (one conventional + one biologic preferred). PsA: ACR criteria + active disease + DMARD failure. Exclude active IBD (IL-17 worsens). Reauth at 16 wk with PASI 75 or ACR20.

How Aetna denies plaque psoriasis + psoriatic arthritis — and how to counter it

Where Aetna pushes back: 1) 'Too new — insufficient long-term data'; 2) Must try Cosentyx or Taltz before Bimzelx; 3) BSA <10% gatekeeping; 4) Active IBD screen.

Counter-arguments that hold up: Bimzelx FDA Oct 17, 2023 plaque + Sep 23, 2024 PsA/axSpA + Nov 19, 2024 HS — full FDA approval, not investigational. BE READY + BE VIVID + BE SURE Lancet 2021 / NEJM 2021 — PASI 90 ~85% wk 16. BE RADIANT (Reich NEJM 2021;385:142-152) — Bimzelx PASI 90 +20 pts OVER Cosentyx (61% vs 49% wk 16, 67% vs 46% wk 48). BE OPTIMAL + BE COMPLETE PsA Lancet 2023 — ACR50 44% biologic-naive. Dual IL-17A+F mechanism captures cytokine evading single-target IL-17A blockade. Special-site bypasses BSA per AAD-NPF 2019.

What Aetna typically denies for plaque psoriasis + psoriatic arthritis

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For plaque psoriasis + psoriatic arthritis, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the plaque psoriasis + psoriatic arthritis treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira
• Enbrel
• Remicade
• Cimzia
• Simponi
• Cosentyx

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.